Immuno-Biological Laboratories Co., Ltd. (JP:4570)
:4570
Want to see JP:4570 full AI Analyst Report?
Top Page
Immuno-Biological Laboratories Co., Ltd.
(4570)
Select Model
Select Model
Rating:58Neutral
Price Target:
¥1,042.00
▼(-25.78% Downside)
Action:Downgraded
Date:05/18/26
The score is driven by improved financial performance (strong profitability recovery and a conservative balance sheet), but is held back by weak technical momentum (below key moving averages with negative MACD) and a relatively expensive valuation (high P/E with a low dividend yield).
Positive Factors
Conservative balance sheet / low leverage
The company's debt-to-equity near 0.10 and a strengthening equity base provide durable financial flexibility. Low leverage reduces refinancing and interest risk, supporting sustained R&D and product supply investment and resilience through industry cycles over the next several months.
Negative Factors
Historical profitability volatility
A recent history of deep losses and a turnaround raises durability risk: earnings may revert if product demand, pricing, or research budgets shift. Investors should note that a strong latest year does not erase past volatility and cyclical exposures inherent in reagents and diagnostics markets.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low leverage
The company's debt-to-equity near 0.10 and a strengthening equity base provide durable financial flexibility. Low leverage reduces refinancing and interest risk, supporting sustained R&D and product supply investment and resilience through industry cycles over the next several months.
Read all positive factors
Immuno-Biological Laboratories Co., Ltd. (4570) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥9.33B
Dividend YieldN/A
Average Volume (3M)23.51K
Price to Earnings (P/E)28.4
Beta (1Y)0.91
Revenue Growth3.66%
EPS Growth32.11%
CountryJP
Employees57
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)27.81
Shares Outstanding9,314,590
10 Day Avg. Volume28,690
30 Day Avg. Volume23,506
Financial Highlights & Ratios
PEG Ratio1.18
Price to Book (P/B)6.78
Price to Sales (P/S)12.44
P/FCF Ratio46.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Immuno-Biological Laboratories Co., Ltd. Business Overview & Revenue Model
Company Description
Immuno-Biological Laboratories Co., Ltd. engages in the research, development, manufacturing, and supply of various immunological research reagents worldwide. The company offers ELILSA, an assay kit to quantitatively measure targeted substances; a...
How the Company Makes Money
The company primarily makes money by selling life-science research and diagnostic-related products, with revenue generated from the manufacture and sale of antibody-based reagents and assay/measurement kits used in laboratories. Sales are typicall...
Immuno-Biological Laboratories Co., Ltd. Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
74
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 951.89M | 1.00B | 969.53M | 816.70M | 794.62M | 647.58M |
| Gross Profit | 632.07M | 700.28M | 628.34M | 517.29M | 526.71M | 376.70M |
| EBITDA | 225.22M | 299.82M | 226.55M | 128.11M | -332.00M | -249.50M |
| Net Income | 258.63M | 329.01M | 249.05M | 186.69M | -289.73M | -258.77M |
Balance Sheet | ||||||
| Total Assets | 1.92B | 2.16B | 1.85B | 1.62B | 1.43B | 1.71B |
| Cash, Cash Equivalents and Short-Term Investments | 903.75M | 989.47M | 825.73M | 734.14M | 614.16M | 508.35M |
| Total Debt | 196.94M | 177.09M | 204.23M | 235.98M | 234.99M | 234.00M |
| Total Liabilities | 343.43M | 311.75M | 332.03M | 354.25M | 355.72M | 336.99M |
| Stockholders Equity | 1.58B | 1.84B | 1.51B | 1.27B | 1.08B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 267.68M | 123.83M | 115.11M | 26.46M | -93.20M |
| Operating Cash Flow | 0.00 | 301.09M | 183.50M | 133.78M | 26.46M | -93.20M |
| Investing Cash Flow | 0.00 | -116.46M | -53.66M | -24.50M | 30.04M | -155.63M |
| Financing Cash Flow | 0.00 | -27.14M | -31.75M | 991.00K | 991.00K | 144.00M |
Immuno-Biological Laboratories Co., Ltd. Technical Analysis
Negative
1404.00
Price Trends
1316.62
Negative
1450.08
Negative
1179.35
Negative
Market Momentum
-100.06
Positive
24.73
Positive
9.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4570, the sentiment is Negative. The current price of 1404 is above the 20-day moving average (MA) of 1152.10, above the 50-day MA of 1316.62, and above the 200-day MA of 1179.35, indicating a bearish trend. The MACD of -100.06 indicates Positive momentum. The RSI at 24.73 is Positive, neither overbought nor oversold. The STOCH value of 9.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4570.
Immuno-Biological Laboratories Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | ¥9.33B | 28.36 | ― | ― | 3.66% | 32.11% | |
54 Neutral | ¥137.64B | -14.34 | ― | 2.18% | -10.48% | -1022.09% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥24.04B | -32.72 | ― | ― | -11.11% | -187.80% | |
45 Neutral | ¥18.49B | -10.19 | ― | ― | ― | 13.18% | |
42 Neutral | ¥12.27B | -20.66 | ― | ― | -25.02% | -697.06% | |
42 Neutral | ¥9.05B | -8.83 | ― | ― | -62.06% | 7.56% |
* Healthcare Sector Average
JP:4570
Immuno-Biological Laboratories Co., Ltd.
1,002.00
493.18
96.93%
JP:4599
StemRIM Inc.
295.00
-16.00
-5.14%
JP:4974
Takara Bio Inc.
1,143.00
356.00
45.24%
JP:4978
ReproCELL Inc.
129.00
-57.00
-30.65%
JP:7774
Japan Tissue Engineering Co., Ltd.
592.00
-6.00
-1.00%
JP:7776
CellSeed Inc.
231.00
-285.00
-55.23%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.